Pyxis Oncology to Present at the Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), today announced that management will present at and host one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021. The presentation will be available on-demand for attendees during the virtual conference beginning on November 18, 2021. A replay of the presentation will be available on the Events and Presentation page on Pyxis Oncology’s website following the conference’s conclusion.

Webcast: https://wsw.com/webcast/jeff201/pyxs/1894104

Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.

Investor Relations Contact:

LifeSci Advisors, LLC

LifeSci Communications